A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors
- Hanley, M.J.
- D'Arcangelo, M.
- Felip, E.
- Garrido, P.
- Zhu, J.
- Ye, M.
- Vranceanu, F.
- Gupta, N.
ISSN: 1552-4604, 0091-2700
Year of publication: 2023
Volume: 63
Issue: 5
Pages: 583-592
Type: Article